The most important question in biopharma is one the industry has historically been reluctant to ask with any rigor. Who are these medicines actually being built for? Dr. Amit Rakhit is a physician and biotech executive with more than two decades of experience across the biopharma industry. That question has followed him through every role he has held, and his answer has shaped a clear and unambiguous position: “Advancing science and advancing health equity are not separate goals. They are the same goal. And it is something all of us in healthcare have a role in shaping together.” Indeed, treating them as anything less is both a moral failure and a strategic one.
Reframe Equity as Strategy, Not Charity
The first and most consequential shift Dr. Amit advocates is a reframing of how the industry positions health equity within its strategic architecture. When equity is treated as a corporate responsibility initiative, a side program running parallel to the real business, it does not last. It gets deprioritized when budgets tighten, restructured when leadership changes, and quietly abandoned when it fails to produce near-term commercial returns. “When equity is treated as a side initiative, it does not last,” Dr. Amit says. “But when we build it into how we innovate and grow, it becomes sustainable.”
Aligning research and development priorities with diseases that disproportionately affect underserved communities does not represent a departure from commercial logic. It expands the addressable opportunity, strengthens the trust relationships that determine long-term market access, and ultimately produces better patient outcomes across broader populations. Health equity embedded in pharma strategy is not a concession to social pressure. It is a more complete and more durable approach to building a biotech business.
The Science Is Only as Good as the Data
The second principle Dr. Amit applies cuts to the technical heart of where health inequity most often originates in the drug development process. Clinical trials that do not reflect the diversity of the patient populations that a treatment is designed to serve produce structurally incomplete science. The efficacy and safety profiles generated from homogeneous trial populations do not translate cleanly to the full range of patients who will ultimately receive the treatment. The gap between the trial population and the real-world population is not an equity problem in isolation. It is a scientific validity problem with direct consequences for patient outcomes. “If the patients in our trials do not reflect the patients we serve, the science is incomplete,” Dr. Amit says.
Prioritizing diversity in clinical trial design and integrating real-world evidence from underrepresented communities from the earliest stages of development is not an add-on to rigorous science. It is what rigorous science requires. The biotech organizations that have internalized that principle are building a more defensible evidentiary base and a more credible regulatory and commercial position as a result.
Listen Before You Design
The third principle Dr. Amit emphasizes is one that requires a genuine shift in how pharma organizations relate to the communities their medicines are designed to serve. Partnering with community health leaders and patient advocates is not a stakeholder management exercise. It is a source of insight that cannot be replicated through internal analysis, however sophisticated. “Partnering with community health leaders and patient advocates brings insights we simply cannot get on our own,” he says. “And those partnerships help us design solutions that truly work.”
Dr. Amit points to failures where solutions designed entirely from within the organization fail at the point of adoption, because the lived experience of the patient community was never genuinely incorporated into the design. Listening is not a soft capability in this context. It is a core competency for any organization serious about delivering health equity at scale rather than describing it in mission statements.
Accountability Is What Converts Intention Into Impact
The thread connecting all three principles is accountability. Good intentions without measurement produce activity rather than outcomes. “What we measure improves,” he says. “When we track progress on equity across trials, talent, and access, we move from good intentions to real impact.”
The vision Dr. Amit has spent his career working toward is one where the question he has carried throughout his time in biopharma finally has a clear and honest answer. A healthcare system that delivers better science, broader access, and better health for everyone. Not as a statement of aspiration, but as a measurable outcome.
Follow Dr. Amit Rakhit on LinkedIn for more insights on health equity, biotech leadership, and mission-driven pharma strategy.
